The Influence of Repeat Surgery and Residual Disease on Recurrence After Breast-Conserving Surgery: A Danish Breast Cancer Cooperative Group Study

Autor: Birgitte Vrou Offersen, Bent Ejlertsen, Karsten Bjerre, Peer Christiansen, Pernille Vahl, Anne Bodilsen, Jens Overgaard

Publikováno v: Bodilsen, A, Bjerre, K, Offersen, B V, Vahl, P, Ejlertsen, B, Overgaard, J & Christiansen, P 2015, ' The Influence of Repeat Surgery and Residual Disease on Recurrence After Breast-Conserving Surgery : A Danish Breast Cancer Cooperative Group Study ', Annals of Surgical Oncology . https://doi.org/10.1245/s10434-015-4707-9

BACKGROUND: A significant proportion of women who have breast-conserving surgery (BCS) subsequently undergo re-excision or proceed to mastectomy. This study aimed to identify factors associated with residual disease after repeat surgery and to determ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c402f4203ed1b6213c9bab7368ca01
https://doi.org/10.1245/s10434-015-4707-9

Abstract P3-06-03: Association between PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients

Autor: Dorte Nielsen, Brett Wallden, Karsten Bjerre, Clt Jørgensen, Shuzhen Liu, Eva Balslev, T. O. Nielsen, Bent Ejlertsen

Publikováno v: Cancer Research. 72:P3-06

Background: Breast cancer can be subclassified into luminal A and B, basal-like and HER2-enriched subtypes, each with distinct biology, prognosis and response to therapy. Pre-clinical studies have suggested that a basal-like subtype is associated wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a232be9db9a66a02516872f955143040
https://doi.org/10.1158/0008-5472.sabcs12-p3-06-03

Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy

Autor: Anita Giobbie-Hurder, Karsten Bjerre, Anne E. Lykkesfeldt, Bent Ejlertsen, Katrine L Henriksen, Mathilde S. Larsen, Anne Vibeke Lænkholm, Birgitte Bruun Rasmussen

Publikováno v: Acta Oncologica. 51:781-789

Estrogen receptor (ER) status is not an optimal marker for response to adjuvant endocrine therapy since approximately 30% of patients with ER-positive tumors eventually relapse. Bcl-2 is regulated by ER and may thus be considered as an indicator of E

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f8b63d6c6cad73553def19081bf5f97
https://doi.org/10.3109/0284186x.2011.653009

Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study

Autor: Ulla Brix Tange, Elisabeth Lidbrink, Anders Bonde Jensen, Jonas Bergh, Erik Wist, Kristin Enevoldsen, Karsten Bjerre, Sven Tyge Langkjer, P.G. Sørensen, Susanne Møller, Martin Andersson, Per Karlsson

Publikováno v: Andersson, M, Lidbrink, E, Bjerre, K, Wist, E, Enevoldsen, K, Jensen, A B, Karlsson, P W, Tange, U B, Sørensen, P G, Møller, S, Bergh, J & Langkjer, S T 2011, ' Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study ', Journal of Clinical Oncology, vol. 29, no. 3, pp. 264-71 . https://doi.org/10.1200/JCO.2010.30.8213

Purpose To evaluate docetaxel or vinorelbine, both with trastuzumab, as first-line therapy of human epidermal growth factor receptor 2–positive advanced breast cancer. Patients and Methods Patients naive to chemotherapy for advanced disease were ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de8a95197ce88271ab3abf53acbfa33b
https://doi.org/10.1200/jco.2010.30.8213

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

Autor: Maj-Britt Jensen, Bent Ejlertsen, Hanne B. Hansen, Susanne Møller, Karsten Bjerre, Martin Jakob Larsen, Peer Christiansen, Henning T. Mouridsen

Publikováno v: Møller, S, Jensen, M-B, Ejlertsen, B, Bjerre, K D, Larsen, M, Hansen, H B, Christiansen, P, Mouridsen, H T & Danish Breast Cancer Cooperative Group 2008, ' The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise ', Acta Odontologica Scandinavica, vol. 47, no. 4, pp. 506-24 . https://doi.org/10.1080/02841860802059259

Udgivelsesdato: 2008-null Introduction. Since 30 years, DBCG (Danish Breast Cancer Cooperative Group) has maintained a clinical database allowing the conduct of quality control studies, of randomised trials, examination of the epidemiology of breast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8be39fe959b112c8b34072fdebb802b4
https://doi.org/10.1080/02841860802059259